S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.

Eric A DeckersKevin P WeversAnneke C Muller KoboldSamantha DamudeOtis M VrielinkRobert J van GinkelLukas B BeenBarbara L van LeeuwenHarald J HoekstraSchelto Kruijff

Published in: Journal of surgical oncology (2019)

S-100B cannot exclude recurrent disease during follow-up of stage III melanoma. However, adding S-100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.

Keyphrases

end stage renal disease
skin cancer
newly diagnosed
high resolution
chronic kidney disease
electron microscopy
peritoneal dialysis
basal cell carcinoma
patient reported outcomes
mass spectrometry